Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Qiagen ( (QGEN) ).
Qiagen N.V. has announced a release of voting rights information as informed by the Netherlands Authority for the Financial Markets (AFM). The notification details BlackRock, Inc.’s indirect holdings and voting rights in Qiagen, reflecting a capital interest of 10.50% and voting rights of 11.54%. This disclosure highlights BlackRock’s significant stake in Qiagen, which may influence the company’s governance and strategic decisions, impacting stakeholders and market perceptions.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its focus on providing solutions for the extraction, purification, and analysis of DNA, RNA, and proteins.
Average Trading Volume: 1,406,775
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.85B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.